1-7 of 7
Barry R. Davies
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical Characterization of AZD9574, a Blood–Brain Barrier Penetrant Inhibitor of PARP1

Anna D. Staniszewska, Domenic Pilger, Sonja J. Gill, Kunzah Jamal, Natacha Bohin, Sofia Guzzetti, Jacob Gordon, Gregory Hamm, Gill Mundin, Giuditta Illuzzi, Andy Pike, Lisa McWilliams, Gareth Maglennon, Jonathan Rose, Glen Hawthorne, Miguel Cortes Gonzalez, Christer Halldin, Peter Johnström, Magnus Schou, Susan E. Critchlow, Stephen Fawell, Jeffrey W. Johannes, Elisabetta Leo, Barry R. Davies, Sabina Cosulich, Jann N. Sarkaria, Mark J. O'Connor, Petra Hamerlik
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (7): 1338–1351.
https://doi.org/10.1158/1078-0432.CCR-23-2094
Published: 01 April 2024
View article titled, Preclinical Characterization of AZD9574, a Blood–Brain Barrier Penetrant Inhibitor of PARP1
Open the PDF for Preclinical Characterization of AZD9574, a Blood–Brain Barrier Penetrant Inhibitor of PARP1 in another window
Includes: Supplementary data
Journal Articles

Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control

Kyoko Nakamura, Ankur Karmokar, Paul M. Farrington, Neil H. James, Antonio Ramos-Montoya, Susan J. Bickerton, Gareth D. Hughes, Timothy M. Illidge, Elaine B. Cadogan, Barry R. Davies, Simon J. Dovedi, Viia Valge-Archer
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (15): 4353–4366.
https://doi.org/10.1158/1078-0432.CCR-20-3701
Published: 01 August 2021
View article titled, Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control
Open the PDF for Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control in another window
Includes: Supplementary data
Journal Articles

AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

Srividya B. Balachander, Steven W. Criscione, Kate F. Byth, Justin Cidado, Ammar Adam, Paula Lewis, Terry Macintyre, Shenghua Wen, Deborah Lawson, Kathleen Burke, Tristan Lubinski, Jeffrey W. Tyner, Stephen E. Kurtz, Shannon K. McWeeney, Jeffrey Varnes, R. Bruce Diebold, Thomas Gero, Stephanos Ioannidis, Edward J. Hennessy, William McCoull, Jamal C. Saeh, Areya Tabatabai, Omid Tavana, Nancy Su, Alwin Schuller, Mathew J. Garnett, Patricia Jaaks, Elizabeth A. Coker, Gareth P. Gregory, Andrea Newbold, Ricky W. Johnstone, Eric Gangl, Martin Wild, Michael Zinda, J. Paul Secrist, Barry R. Davies, Stephen E. Fawell, Francis D. Gibbons
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (24): 6535–6549.
https://doi.org/10.1158/1078-0432.CCR-20-0863
Published: 15 December 2020
View article titled, AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia
Open the PDF for AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia in another window
Includes: Supplementary data
Journal Articles

Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts

Albert Gris-Oliver, Marta Palafox, Laia Monserrat, Fara Brasó-Maristany, Andreu Òdena, Mònica Sánchez-Guixé, Yasir H. Ibrahim, Guillermo Villacampa, Judit Grueso, Mireia Parés, Marta Guzmán, Olga Rodríguez, Alejandra Bruna, Caroline S. Hirst, Alan Barnicle, Elza C. de Bruin, Avinash Reddy, Gaia Schiavon, Joaquín Arribas, Gordon B. Mills, Carlos Caldas, Rodrigo Dienstmann, Aleix Prat, Paolo Nuciforo, Pedram Razavi, Maurizio Scaltriti, Nicholas C. Turner, Cristina Saura, Barry R. Davies, Mafalda Oliveira, Violeta Serra
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (14): 3720–3731.
https://doi.org/10.1158/1078-0432.CCR-19-3324
Published: 15 July 2020
View article titled, Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts
Open the PDF for Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts in another window
Includes: Supplementary data
Journal Articles

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers

Udai Banerji, Emma J. Dean, J. Alejandro Pérez-Fidalgo, Gerald Batist, Philippe L. Bedard, Benoit You, Shannon N. Westin, Peter Kabos, Michelle D. Garrett, Mathew Tall, Helen Ambrose, J. Carl Barrett, T. Hedley Carr, S.Y. Amy Cheung, Claire Corcoran, Marie Cullberg, Barry R. Davies, Elza C. de Bruin, Paul Elvin, Andrew Foxley, Peter Lawrence, Justin P.O. Lindemann, Rhiannon Maudsley, Martin Pass, Vicky Rowlands, Paul Rugman, Gaia Schiavon, James Yates, Jan H.M. Schellens
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (9): 2050–2059.
https://doi.org/10.1158/1078-0432.CCR-17-2260
Published: 30 April 2018
View article titled, A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <em>PIK3CA</em>-Mutated Breast and Gynecologic Cancers
Open the PDF for A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <em>PIK3CA</em>-Mutated Breast and Gynecologic Cancers in another window
Includes: Supplementary data
Journal Articles

Blocked Autophagy Using Lysosomotropic Agents Sensitizes Resistant Prostate Tumor Cells to the Novel Akt Inhibitor AZD5363

Francois Lamoureux, Christian Thomas, Claire Crafter, Masafumi Kumano, Fan Zhang, Barry R. Davies, Martin E. Gleave, Amina Zoubeidi
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (4): 833–844.
https://doi.org/10.1158/1078-0432.CCR-12-3114
Published: 14 February 2013
View article titled, Blocked Autophagy Using Lysosomotropic Agents Sensitizes Resistant Prostate Tumor Cells to the Novel Akt Inhibitor AZD5363
Open the PDF for Blocked Autophagy Using Lysosomotropic Agents Sensitizes Resistant Prostate Tumor Cells to the Novel Akt Inhibitor AZD5363 in another window
Includes: Supplementary data
Journal Articles

Evaluation of the Therapeutic Potential of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Preclinical Models of Bladder Cancer

Jose L. Dominguez-Escrig, John D. Kelly, David E. Neal, Sonya M. King, Barry R. Davies
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (14): 4874–4884.
https://doi.org/10.1158/1078-0432.CCR-04-0034
Published: 21 July 2004
View article titled, Evaluation of the Therapeutic Potential of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Preclinical Models of Bladder Cancer
Open the PDF for Evaluation of the Therapeutic Potential of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Preclinical Models of Bladder Cancer in another window